Survanta Injection 25 mg/ml contains Phospholipids, a natural surfactant preparation used for the prevention and treatment of neonatal respiratory distress syndrome (RDS) in premature infants. Phospholipids in Survanta help reduce surface tension within the alveoli, preventing alveolar collapse during exhalation, improving lung compliance, and enhancing oxygenation.

Survanta is particularly crucial for preterm neonates with insufficient endogenous surfactant production, supporting proper lung function and increasing survival rates. Administered via intratracheal instillation, it quickly spreads over the alveolar surface, ensuring effective respiratory support.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Benefits

• Restores Lung Function: Supplements deficient surfactant in premature infants’ lungs.

• Prevents Alveolar Collapse: Reduces surface tension, improving lung compliance.

• Enhances Oxygenation: Improves gas exchange and respiratory efficiency.

• Supports Neonatal Survival: Reduces morbidity and mortality in RDS.

• Rapid Onset of Action: Provides immediate improvement in lung function after administration.

Indications

Survanta Injection 25 mg/ml is indicated for:

• Prevention of neonatal respiratory distress syndrome in preterm infants at risk

• Treatment of established respiratory distress syndrome in premature neonates

• Supportive therapy in infants requiring improved lung compliance and oxygenation

It is used under intensive care conditions, often in combination with mechanical ventilation or other respiratory support measures.

Dosage and Administration

• Administered via intratracheal instillation by trained healthcare professionals in a neonatal intensive care unit (NICU).

• Typical initial dose: 4 ml/kg body weight (100 mg/kg phospholipid) for prevention or treatment.

• Repeat doses may be given at 6–12 hour intervals depending on clinical response.

• Dosage and administration should strictly follow established neonatal care protocols.

• Continuous monitoring of oxygenation, ventilation, and vital signs is essential.

Possible Side Effects

Survanta Injection is generally well tolerated in neonates. Common side effects may include:

• Transient bradycardia or desaturation during administration

• Minor airway obstruction if the surfactant is not properly instilled

• Temporary changes in blood pressure or heart rate

Serious adverse events are rare but may include pulmonary hemorrhage or lung injury if dosing is incorrect. Continuous monitoring minimizes risk.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use only in a hospital setting with appropriate neonatal intensive care facilities.

• Ensure correct dosing and proper intratracheal administration technique.

• Monitor infants closely for signs of respiratory improvement or adverse reactions.

• Avoid contamination; use aseptic technique during preparation and administration.

• Not intended for adults or children; strictly for neonatal use under medical supervision.

Storage

Store Survanta Injection 25 mg/ml in a refrigerator at 2–8°C. Do not freeze. Protect from light. Use immediately after opening. Keep out of reach of children.